Drug intelligence / Profile preview

Recombinant Rabies G Protein Vaccine

Development stage: Preclinical
Lead developer: Cadila Pharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This is a vaccine candidate designed to provide immunity against rabies by expressing the rabies virus glycoprotein. It works by inducing both humoral and cell-mediated immune responses, crucial for protecting against rabies infection. The vaccine aims to replace traditional multi-dose inactivated vaccines with a potentially safer and more efficient single-dose regimen[1][2].

Beyond the preview

Go deeper on Recombinant Rabies G Protein Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recombinant Rabies G Protein Vaccine.

Explore the full profile